Methal N. Albarghouthi
Methal N. Albarghouthi publishes mostly in Biomedical Engineering, Molecular Biology and Radiology, Nuclear Medicine and Imaging, on topics such as Microfluidic and Capillary Electrophoresis Applications, Protein purification and stability and Monoclonal and Polyclonal Antibodies Research.
- World rank
- #1,611,286 of 7,710,434 ranked researchers
- Rank in United States
- #500,975 of 1,627,098
- Works
- 18
- Citations
- 1k
- Citations per work
- 56.3
What does Methal N. Albarghouthi research?
Methal N. Albarghouthi's work is mostly in Engineering (44%), Biochemistry, Genetics and Molecular Biology (22%), Medicine (17%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Physical Sciences1053.7%
- Engineering844.4%
- Chemistry29.3%
- Life Sciences424.1%
- Health Sciences316.7%
- Medicine316.7%
- Everything else15.5%
- 1Biomedical Engineering44% of their works
- 2Molecular Biology22% of their works
- 3Radiology, Nuclear Medicine and Imaging13% of their works
- 4Spectroscopy9% of their works
- 5Oncology4% of their works
- 6Immunology2% of their works
Research topics
- Microfluidic and Capillary Electrophoresis Applications
- Protein purification and stability
- Monoclonal and Polyclonal Antibodies Research
- Innovative Microfluidic and Catalytic Techniques Innovation
- Microfluidic and Bio-sensing Technologies
- Nanopore and Nanochannel Transport Studies
- Advanced Proteomics Techniques and Applications
- Glycosylation and Glycoproteins Research
Which keywords describe Methal N. Albarghouthi's research?
The keywords of their largest research topics: Monoclonal Antibodies, Therapeutic Antibodies, Lab-on-a-Chip, Microfluidics, Biomedical Research, Glycosylation, Poly(dimethylsiloxane) and Biopharmaceuticals.
- Cancer
- Mass Spectrometry
- Nanofluidics
- Acoustic Manipulation
- Continuous Flow Chemistry
- Antibody Engineering
- Biopharmaceuticals
- Glycosylation
- Microfluidics
- Therapeutic Antibodies
- Monoclonal Antibodies
- Lab-on-a-Chip
- Biomedical Research
- Poly(dimethylsiloxane)
- Protein Aggregation
- Fc Receptors
- Droplet Formation
- Particle Separation
- Nanopores
- Proteomics
- Glycans
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 21 words, with their numbers
- Monoclonal Antibodies152 topics
- Therapeutic Antibodies152 topics
- Lab-on-a-Chip142 topics
- Microfluidics112 topics
- Biomedical Research91 topic
- Glycosylation92 topics
- Poly(dimethylsiloxane)91 topic
- Biopharmaceuticals81 topic
- Protein Aggregation81 topic
- Antibody Engineering71 topic
- Fc Receptors71 topic
- Continuous Flow Chemistry61 topic
- Droplet Formation61 topic
- Acoustic Manipulation51 topic
- Particle Separation51 topic
- Nanofluidics41 topic
- Nanopores41 topic
- Mass Spectrometry31 topic
- Proteomics31 topic
- Cancer21 topic
- Glycans21 topic
Where does Methal N. Albarghouthi work?
Methal N. Albarghouthi's main affiliation in the publication record is AstraZeneca (United States), United States.
How many publications and citations does Methal N. Albarghouthi have?
OpenAlex counts 18 works and 1,014 citations for Methal N. Albarghouthi, an h-index of 12, ranking #1,611,286 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Methal N. Albarghouthi. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.